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In this communication, we report the synthesis and characterization of a library of small molecule antago-
nists of the human gonadotropin releasing hormone receptor based upon the 2-(4-tert-butylphenyl)-4-
piperazinyl-benzimidazole scaffold via Cu-catalysed azide alkyne cycloaddition. Our main purpose was to
find a more soluble compound based on the WAY207024 lead with nanomolar potency to inhibit the
GnRH receptor. A late stage diversification by the use of click chemistry was, furthermore developed to al-
low for expansion of the library in future optimisations. All compounds were tested in a functional assay to
determine the individual potency of inhibiting stimulation of the receptor by the endogenous agonist
GnRH. In conclusion, we found that compound 8a showed improved solubility compared to WAY207024
and nanomolar affinity to GnRH receptor.
Gonadotropin-releasing hormone (GnRH) is a peptide
hormone secreted from the hypothalamus into the
hypophysial portal bloodstream. Once in circulation, the
peptide acts as an endocrine signalling hormone mediating
release of follicle stimulating hormone (FSH) and luteinizing
hormone (LH) via gonadotropin-releasing hormone receptor
(GnRHR) activation in the pituitary gland. LH and FSH di-
rectly regulate gender-specific production of androgens, estro-
gens, progesterone and inhibin in the gonads. The regulatory
circuit is closed by the permeability of the blood–brain barrier
to steroid hormones such as estrogen and testosterone, which
form negative feedback loops. GnRH, LH and FSH are un-
likely to permeate the blood–brain barrier, thus impeding any
regulatory feedback on hormone balance, which substantiates
the impact of testosterone and estrogen on neurochemical
correlates of their respective effects on social behaviour,
decision-making and ageing. The hypothalamic–pituitary–go-
nadal (HPG) signalling circuit is key to gender hormone ho-
meostasis, which can lead to substantial implications in cog-
nitive and behavioural traits.1–4
GnRH agonists are well-established pharmaceuticals used
at low dose to stimulate hypofunctional GnRH in
hypogonadism. At high dose, GnRH agonists deplete GnRH
receptor function in the pituitary, limiting LH and FSH secre-
tion and thereby the levels of androgens and estrogens in cir-
culation and suppressing hormone production completely.
GnRH receptor agonists play an important role in clinical
care, e.g. in the treatment of hormone responsive cancer, re-
productive diseases and for behavioral modification of sexual
offenders via these mechanisms. However, GnRH agonists
cannot address mild GnRH overfunction, which would re-
quire attenuation of the signaling circuit, rather than stimu-
lation or depletion. To address this shortcoming, GnRH an-
tagonists have attracted considerable attention in recent
years specifically to treat diseases, which require some reduc-
tion of GnRH stimulation.5–8
We were interested in the development of a GnRH antago-
nist of moderate potency to address cognitive and behavioral
correlates of GnRH-R attenuation. In our reasoning, a revers-
ibly binding antagonist would reduce gonadal
overstimulation by limiting the availability of binding sites
by competition with the agonist. Thereby, the central effects
of testosterone and estrogen would be buffered, while hor-
mone homeostasis would be preserved. Small molecule an-
tagonists of GnRHR are particularly interesting due to their
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direct, dose dependent inhibition of GnRH activity, lack of
stimulatory side effects on the receptor and superior passive
permeability into tissues relative to peptide agonists.
Several classes of small molecule antagonists have been
developed previously. Pelletier and co-workers reported a
2-(4-tert-butylphenyl)-4-piperazinyl-benzimidazole-scaffold as a
small molecule antagonist of the GnRHR with nanomolar in-
hibition potency, albeit low solubility was cited as a short-
coming by the authors.9,10 Further optimization lead to the
discovery of the slightly more soluble WAY 207024 compound
as shown in Fig. 1.11
Based on these results, we have designed a novel library of
potential antagonists addressing the following criteria:
a) A late stage diversification approach based on the
1,3-triazole motive to facilitate straightforward structural
modification.
b) A moderate potency permitting competition of the li-
gand in circulation with endogenous GnRH for GnRHR bind-
ing sites, which would make GnRH activation subject to both
GnRH concentration and the concentration of the inhibitor
in tissue.
c) Improved solubility in aqueous media to improve bio-
availability and pharmacokinetic profile of the lead.
Fig. 1 shows the title scaffold and some relevant properties
discussed herein. As apparent from the high partitioning coeffi-
cient logP, the compound is highly lipophilic, which may ham-
per solubility in aqueous formulation as well as non-specific
binding of the compound in vivo. In previous studies, it was
found that the body of the scaffold (blue oval, A) is central to
binding selectively the GnRH receptor, whereas structural mod-
ifications in the upper section of the lead (green oval, B) with
planar, hydrogen bonding functional groups were found to be
beneficial for modulating antagonist potency.
We surmised that the 1,3-functionalised triazole moiety
would resemble well the planar geometry required for suc-
cessful structural modification and simultaneously allow for
introducing a broad spectrum of structural variations in the
last synthetic stage using one robust reaction. Since the 1,3-
functionalised triazole is obtained via the Cu-catalysed azide-
alkyne cycloaddition reaction, we opted for working with a
building block based on A to obtain an alkyne substrate for
the reaction.
The overall design strategy in this communication was to
generate triazoles from different functionalized azides that
would be beneficial for the potency to inhibit the GnRH re-
ceptor while improving the aqueous solubility. We incorpo-
rated a variety of azides via click chemistry, including sugar
moieties, which have been thoroughly demonstrated to effect
favourable solubility characteristics and are discussed exten-
sively in the literature.12–15 Furthermore, the reduced solubil-
ity of the alkyl and aromatic azides would also counteract our
intention to improve aqueous solubility through reducing
clog P (and hence, the bioavailability and pharmacokinetically
desirable profile).
The desired intermediate (7) was synthesised in 19% over-
all yield over six steps on a multigram scale. In brief, 2,5-
difluoronitrobenzene was converted to phenylene diamine 4
over three steps as described previously.9 Contrary to the
published method, we found that the oxidative conversion of
4 into imidazole 6 proceeded smoothly in absence of a transi-
tion metal catalyst with air as the oxidant. The observation of
6b as a minor by-product suggests a Cannizarro-like side re-
action.16 The route is shown in Scheme 1.
A further modification was made relative to literature to
facilitate cleavage of the BOC protecting group. Substitution
of the TFA used originally with HCl in dioxane gave a
colourless solid instead of an oily product, which benefits the
scalability of this route. Notably, compound 4 is fully
converted into heterocyclic products, although the competing
formation of 6b in about 8% yield limits the overall yield of
6a to 75% over two steps. Intermediate 7 was synthesized by
Fig. 1 Key properties and molecular structure of WAY 207024, the
lead compound for GnRH antagonist development. A (blue oval)
depicts the scaffold body; B (green oval) depicts the moiety of interest
for further structural optimization. IC50 – concentration to inhibit
GnRH binding to the receptor by 50%. hGnRH – human GnRH
receptor. rGnRH – rat GnRH receptor. PSA – polar surface area in Å2.
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alkylation with propargyl bromide in dry DMF using potas-
sium carbonate as base in 51% yield to furnish the desired
substrate 7 for azide alkyne cycloaddition.
With a robust and high yielding route to gram amounts of
7 in hand, further diversification using the copper-catalysed
azide-alkyne cycloaddition (CuAAC) reaction with a range of
commercially available azide substrates became possible. See
Scheme 2 for an overview.
Since products 8a–8j were obtained in more than suffi-
cient yields for biological testing following a published proto-
col, no attempts to optimise the reaction were made at this
point.
Following synthesis and characterisation, inhibition of re-
ceptor activation by LHRH/GnRH was measured in division
arrested cell lines from Multispan Inc. stably expressing func-
tional hGnRH receptors. As described in the literature, the
solubility of 1 and some of its derivatives is rather poor,
which lead to a cut-off at 5 × 103 nM for the maximum con-
centration in the cell culture assay. Compounds insoluble in
DMSO at 10 mM were dropped from testing. Nonetheless,
concentration dependent competition studies were
performed in vitro in presence of 5 nM LnRH antagonist with
the remainder of derivatives. Compounds showing a pIC50 >
5 were tested again over a wide range of concentrations (loga-
rithmic, 0.1–103 nM). A one-site competitive inhibition model
was found to work best for fitting of the data curves. To
Scheme 2 Diversification of the scaffold body using CuAAC.
Fig. 2 Investigated molecular entities, isolated yields, inhibition potency, inhibition constant and properties computed for evaluation. For
comparison, test results of lead 1 (green box) and positive controls 8k and 8l should be considered. aReference value from literature.17,18 IC50
values are given as the geometric mean of two experiments, see ESI† for details. Ki was calculated from mean value using the Cheng–Prusoff
equation (Ki = IC50/(1 + [L]/Kd)).
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evaluate the obtained inhibition potency values and to vali-
date the assay, we included the well-described, commercially
available GnRH antagonists T98475 (8k) and AG04557 (8l) as
independent, positive controls and the metabolically stable
peptide agonist buserelin as negative control. The lead com-
pound WAY207024 (1) was included as a reference in the cell
assay. All IC50 values obtained for each test compound in the
concentration dependent screening were converted into Ki
values using the equation of Cheng and Prusoff.15
As illustrated in Fig. 2, compounds derived from 1 using
CuAAC were found to exhibit competitive antagonism
against the endogeneous agonist GnRH. While alkyl pipera-
zines 7a and 7b show only moderate potency, 21 and 43-fold
lower than 1, respectively, their clogP values are lower than
that of 1, which results in higher solubility (>100 nM). In
line with our working hypothesis, the introduction of a pla-
nar triazole-core has a positive effect on potency. The
2-fluoroethyl triazole 8a is equally potent as 1, Interestingly
the thermodynamic solubility assay showed that 8a is 1.5
times more soluble than 1, 3 μg ml−1 at pH 7.4 (phosphate
buffered saline) and 2.098 mg mL−1 at pH 1.2 (simulated gas-
tric fluid) which was indicated by the lower clog P-value. The
introduction of an N-BOC-Ala functionalised triazole 8b fur-
ther improves polarity, albeit at the cost of a drop of one or-
der of magnitude in potency. While these results may indi-
cate that the triazole moiety is a useful pharmacophore, its
vicinity was found to be much less tolerant to the introduc-
tion of pyranose moieties (8c–f), which was attempted to im-
prove solubility. While these sugar derivatives lead to a major
improvement of polarity as indicated by clogP values be-
tween 2 and 5, their potency to inhibit GnRH binding
dropped out of the desired range. Masking the polyol as a
tetraacetate (8c) helped with retaining potency, which does
not bode well for making use of the solubility improvement
by glycosylation. However, when varying the azide component
to a synthetic glycoside to obtain 8g, a viable compromise be-
tween solubility and inhibition potency was obtained. Deriva-
tive 8g was measured to be soluble at pH 1.2, 1.2 mg ml−1
and <1 μg ml−1 at pH 7.4. With a potency of 38 nM, barely
threefold lower than that of 1, this hit may create an opening
for further exploration using a library of diverse analogues of
8g. Products 8h–j, obtained from aromatic and hetero-
aromatic azides and 7, did not lead to increased solubility or
affinities compared to WAY207024.
In conclusion, 18 analogues were synthesized using an ap-
proach of late-stage diversification via CuAAC and evaluated
for potency to inhibit hGnRHR activation. While molecular
diversity can easily be introduced into the scaffold body via
this route few compounds with hGnRH inhibition potency in
the desired range were identified indicating limited tolerance
for structural modification in the vicinity of the triazole. The
pyranose derivatives did not give the desired inhibition to the
GnRH receptors neither did the less soluble compounds 8h
and 8i. Nonetheless, compounds 8a and 8g emerge as highly
promising candidates for further investigation in behavioural
animal models as a couple of GnRH modulating antagonists.
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